"Cresols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any of three isomeric crystalline aromatic methylphenols, also known as hydroxytoluenes.
| Descriptor ID |
D003408
|
| MeSH Number(s) |
D02.455.426.559.389.657.239
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cresols".
Below are MeSH descriptors whose meaning is more specific than "Cresols".
This graph shows the total number of publications written about "Cresols" by people in this website by year, and whether "Cresols" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cresols" by people in Profiles.
-
Madero M, Cano KB, Campos I, Tao X, Maheshwari V, Brown J, Cornejo B, Handelman G, Thijssen S, Kotanko P. Removal of Protein-Bound Uremic Toxins during Hemodialysis Using a Binding Competitor. Clin J Am Soc Nephrol. 2019 03 07; 14(3):394-402.
-
DuBeau CE, Morrow JD, Kraus SR, Creanga D, Bavendam T. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials. Neurourol Urodyn. 2012 Nov; 31(8):1258-65.
-
Kruse A, Tao X, Bhalani V, Handelman G, Levin NW, Kotanko P, Thijssen S. Clearance of p-cresol sulfate and ?-2-microglobulin from dialysate by commercially available sorbent technology. ASAIO J. 2011 May-Jun; 57(3):219-24.
-
Reddy PP, Borgstein NG, Nijman RJ, Ellsworth PI. Long-term efficacy and safety of tolterodine in children with neurogenic detrusor overactivity. J Pediatr Urol. 2008 Dec; 4(6):428-33.
-
Nijman RJ, Borgstein NG, Ellsworth P, Siggaard C. Long-term tolerability of tolterodine extended release in children 5-11 years of age: results from a 12-month, open-label study. Eur Urol. 2007 Nov; 52(5):1511-6.
-
Zhang YA, Tuft RA, Lifshitz LM, Fogarty KE, Singer JJ, Zou H. Caffeine-activated large-conductance plasma membrane cation channels in cardiac myocytes: characteristics and significance. Am J Physiol Heart Circ Physiol. 2007 Oct; 293(4):H2448-61.
-
Ellsworth PI, Borgstein NG, Nijman RJ, Reddy PP. Use of tolterodine in children with neurogenic detrusor overactivity: relationship between dose and urodynamic response. J Urol. 2005 Oct; 174(4 Pt 2):1647-51; discussion 1651.
-
Nijman RJ, Borgstein NG, Ellsworth P, Djurhuus JC. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials. J Urol. 2005 Apr; 173(4):1334-9.
-
DuBeau CE, Khullar V, Versi E. "Unblinding" in randomized controlled drug trials for urinary incontinence: Implications for assessing outcomes when adverse effects are evident. Neurourol Urodyn. 2005; 24(1):13-20.
-
Ellsworth P. RE: Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence. J Urol. 2003 Sep; 170(3):928; author reply 928.